ArticleCureus2025
Concurrent Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy Induced by Cytomegalovirus and Epstein-Barr Virus Co-infection in an Immunocompetent Young Adult: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) and thrombotic microangiopathy (TMA) are rare and life-threatening conditions that can be triggered by viral infections, though their simultaneous occurrence remains exceptional, particularly in immunocompetent individuals. We report the case of a previously healthy 19-year-old woman who developed severe anemia, thrombocytopenia, and fever, rapidly progressing to status epilepticus and multiorgan failure. Laboratory findings were consistent with microangiopathic hemolytic anemia (MAHA), with a normal ADAMTS13 activity, and brain imaging demonstrated diffuse cerebral vasculitis with microthrombi. Extensive workup excluded autoimmune, malignant, toxic, and other infectious causes, while polymerase chain reaction (PCR) testing revealed significant cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viremia. In parallel, the patient fulfilled six of the eight HLH-2004 criteria, including persistent fever, bi-cytopenia, hepatosplenomegaly, hyperferritinemia, hypertriglyceridemia, and hemophagocytosis on bone marrow examination, with an HScore of 259 (>99% probability of HLH), confirming the diagnosis of secondary HLH. Treatment included corticosteroids, ganciclovir, rituximab, cyclophosphamide, anticoagulation, and supportive care, resulting in gradual clinical improvement and full recovery. This case illustrates the pathogenic synergy between CMV and EBV in precipitating both HLH and TMA in an immunocompetent host, and highlights the importance of early diagnosis and multidisciplinary management in such rare and aggressive presentations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.